RxDoctor Payments Data

Brent Goodman, MD

Neurology · Scottsdale, AZNPI 1457334799

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $153,640 of the $198,478 with a category attached, or 77.4%. AstraZeneca accounts for 99.9% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $172,114, more than ten times the $46 reported in 2019. Among neurology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$198,478in general payments, 2019–2025

Across 152 payments — averaging $1305.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$198K
  • Pharming Healthcare, Inc.$90
  • Argenx US, Inc.$48
  • Akcea Therapeutics, Inc.$46
  • Cycle Pharmaceuticals Inc$28
  • Biocryst US Sales Co., LLC$27
  • plus $40 from 2 others
$345,850in research payments, 2019–2025

Across 29 payments — averaging $11,926 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$314K
  • Argenx US, Inc.$18K
  • Regeneron$14K

What the payments were for

  • Consulting fees$12,3516%
  • Speaking & faculty fees$153,64077%
  • Travel & lodging$29,47715%
  • Food & beverage$3,0112%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$198,478 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$282,653
Medicare patients
122
Services billed
378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pyridostigmine Bromide49$6,525
Cromolyn Sodium17$5,390
Midodrine Hcl17$2,185
Clonidine11$1,176
Mycophenolate Mofetil12$291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Cycle Pharmaceuticals IncCromolyn Sodium$28$5,39017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 neurology providers in Arizona.

Other neurology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →